The identification of unique serum proteins of HIV-1 latently infected long-term non-progressor patients

AIDS Research and Therapy

Volumn 7, Issue , 2010, Pages

  Van Duyne, Rachel ^a,b   Guendel, Irene ^b   Kehn Hall, Kylene ^b   Easley, Rebecca ^b   Klase, Zachary ^c   Liu, Chenglong ^d   Young, Mary ^d   Kashanchi, Fatah ^b,e  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^b GEORGE MASON UNIVERSITY   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^e National Center for Biodefense and Infectious Diseases Professor of Microbiology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; FASCAPLYSIN; PLASMA PROTEIN;

APOPTOSIS; ARTICLE; CELL VIABILITY; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; INFECTION RESISTANCE; LATENT VIRUS INFECTION; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEOMICS; TWO DIMENSIONAL GEL ELECTROPHORESIS; VIRUS CELL INTERACTION; VIRUS REPLICATION;

EID: 77954205887     PISSN: 17426405     EISSN: None     Source Type: Journal    
DOI: 10.1186/1742-6405-7-21     Document Type: Article

References (62)

1. Adkins JN, Varnum SM, Auberry KJ, Moore RJ, Angell NH, Smith RD, Springer DL, Pounds JG. Toward a human blood serum proteome: analysis by multidimensional separation coupled with mass spectrometry. Mol Cell Proteomics 2002, 1:947-955. 10.1074/mcp.M200066-MCP200, 12543931.
2. Tanaka Y, Akiyama H, Kuroda T, Jung G, Tanahashi K, Sugaya H, Utsumi J, Kawasaki H, Hirano H. A novel approach and protocol for discovering extremely low-abundance proteins in serum. Proteomics 2006, 6:4845-4855. 10.1002/pmic.200500774, 16878292.
3. Sasaki K, Sato K, Akiyama Y, Yanagihara K, Oka M, Yamaguchi K. Peptidomics-based approach reveals the secretion of the 29-residue COOH-terminal fragment of the putative tumor suppressor protein DMBT1 from pancreatic adenocarcinoma cell lines. Cancer Res 2002, 62:4894-4898.
4. Kennedy S. The role of proteomics in toxicology: identification of biomarkers of toxicity by protein expression analysis. Biomarkers 2002, 7:269-290. 10.1080/13547500210127318, 12171755.
5. Jacobs JM, Adkins JN, Qian WJ, Liu T, Shen Y, Camp DG, Smith RD. Utilizing human blood plasma for proteomic biomarker discovery. J Proteome Res 2005, 4:1073-1085. 10.1021/pr0500657, 16083256.
6. Ardekani AM, Liotta LA, Petricoin EF. Clinical potential of proteomics in the diagnosis of ovarian cancer. Expert Rev Mol Diagn 2002, 2:312-320. 10.1586/14737159.2.4.312, 12138495.
7. Jacobs IJ, Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics 2004, 3:355-366. 10.1074/mcp.R400006-MCP200, 14764655.
8. Rosenblatt KP, Bryant-Greenwood P, Killian JK, Mehta A, Geho D, Espina V, Petricoin EF, Liotta LA. Serum proteomics in cancer diagnosis and management. Annu Rev Med 2004, 55:97-112. 10.1146/annurev.med.55.091902.105237, 14746511.
9. Lathrop JT, Anderson NL, Anderson NG, Hammond DJ. Therapeutic potential of the plasma proteome. Curr Opin Mol Ther 2003, 5:250-257.
10. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002, 1:845-867. 10.1074/mcp.R200007-MCP200, 12488461.
11. Zhang Z, Bast RC, Yu Y, Li J, Sokoll LJ, Rai AJ, Rosenzweig JM, Cameron B, Wang YY, Meng XY, Berchuck A, Van Haaften-Day C, Hacker NF, de Bruijn HW, van der Zee AG, Jacobs IJ, Fung ET, Chan DW. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004, 64:5882-5890. 10.1158/0008-5472.CAN-04-0746, 15313933.
12. Whitehouse C, Solomon E. Current status of the molecular characterization of the ovarian cancer antigen CA125 and implications for its use in clinical screening. Gynecol Oncol 2003, 88:S152-157. 10.1006/gyno.2002.6708, 12586109.
13. Grossklaus DJ, Smith JA, Shappell SB, Coffey CS, Chang SS, Cookson MS. The free/total prostate-specific antigen ratio (%fPSA) is the best predictor of tumor involvement in the radical prostatectomy specimen among men with an elevated PSA. Urol Oncol 2002, 7:195-198. 10.1016/S1078-1439(02)00190-4, 12644216.
14. Liu Z, Tian Y, Wang B, Yan Z, Qian D, Ding S, Song X, Bai Z, Li L. Serum proteomics with SELDI-TOF-MS in congenital human cytomegalovirus hepatitis. J Med Virol 2007, 79:1500-1505. 10.1002/jmv.20927, 17705191.
15. Pang RT, Poon TC, Chan KC, Lee NL, Chiu RW, Tong YK, Wong RM, Chim SS, Ngai SM, Sung JJ, Lo YM. Serum proteomic fingerprints of adult patients with severe acute respiratory syndrome. Clin Chem 2006, 52:421-429. 10.1373/clinchem.2005.061689, 16423906.
16. Cheung KJ, Tilleman K, Deforce D, Colle I, Van Vlierberghe H. The HCV serum proteome: a search for fibrosis protein markers. J Viral Hepat 2009, 16:418-429. 10.1111/j.1365-2893.2009.01083.x, 19226329.
17. Huang Y, Paxton WA, Wolinsky SM, Neumann AU, Zhang L, He T, Kang S, Ceradini D, Jin Z, Yazdanbakhsh K, Kunstman K, Erickson D, Dragon E, Landau NR, Phair J, Ho DD, Koup RA. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 1996, 2:1240-1243. 10.1038/nm1196-1240, 8898752.
18. Yamada T, Iwamoto A. Comparison of proviral accessory genes between long-term nonprogressors and progressors of human immunodeficiency virus type 1 infection. Arch Virol 2000, 145:1021-1027. 10.1007/s007050050692, 10881687.
19. Mologni D, Citterio P, Menzaghi B, Zanone Poma B, Riva C, Broggini V, Sinicco A, Milazzo L, Adorni F, Rusconi S, Galli M, Riva A. Vpr and HIV-1 disease progression: R77Q mutation is associated with long-term control of HIV-1 infection in different groups of patients. Aids 2006, 20:567-574. 10.1097/01.aids.0000210611.60459.0e, 16470121.
20. Lum JJ, Cohen OJ, Nie Z, Weaver JG, Gomez TS, Yao XJ, Lynch D, Pilon AA, Hawley N, Kim JE, Chen Z, Montpetit M, Sanchez-Dardon J, Cohen EA, Badley AD. Vpr R77Q is associated with long-term nonprogressive HIV infection and impaired induction of apoptosis. J Clin Invest 2003, 111:1547-1554. 155040, 12750404.
21. Kestler HW, Ringler DJ, Mori K, Panicali DL, Sehgal PK, Daniel MD, Desrosiers RC. Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell 1991, 65:651-662. 10.1016/0092-8674(91)90097-I, 2032289.
22. Deacon NJ, Tsykin A, Solomon A, Smith K, Ludford-Menting M, Hooker DJ, McPhee DA, Greenway AL, Ellett A, Chatfield C, Lawson VA, Crowe S, Maerz A, Sonza S, Learmont J, Sullivan JS, Cunningham A, Dwyer D, Dowton D, Mills J. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 1995, 270:988-991. 10.1126/science.270.5238.988, 7481804.
23. Stewart GJ, Ashton LJ, Biti RA, Ffrench RA, Bennetts BH, Newcombe NR, Benson EM, Carr A, Cooper DA, Kaldor JM. Increased frequency of CCR-5 delta 32 heterozygotes among long-term non-progressors with HIV-1 infection. The Australian Long-Term Non-Progressor Study Group. Aids 1997, 11:1833-1838. 10.1097/00002030-199715000-00007, 9412701.
24. Mazzucchelli R, Corvasce S, Violin M, Riva C, Bianchi R, Deho L, Velleca R, Cibella J, Bada M, Moroni M, Galli M, Balotta C. Role of CCR5, CCR2 and SDF-1 gene polymorphisms in a population of HIV-1 infected individuals. J Biol Regul Homeost Agents 2001, 15:265-271.
25. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, Goedert JJ, Buchbinder SP, Vittinghoff E, Gomperts E, Donfield S, Vlahov D, Kaslow R, Saah A, Rinaldo C, Detels R, O'Brien SJ. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996, 273:1856-1862. 10.1126/science.273.5283.1856, 8791590.
26. Munkanta M, Terunuma H, Takahashi M, Hanabusa H, Miura T, Ikeda S, Sakai M, Fujii T, Takahashi Y, Oka S, Matsuda J, Ishikawa M, Taki M, Takashima Y, Mimaya J, Ito M, Kimura A, Yasunami M. HLA-B polymorphism in Japanese HIV-1-infected long-term surviving hemophiliacs. Viral Immunol 2005, 18:500-505. 10.1089/vim.2005.18.500, 16212528.
27. Migueles SA, Sabbaghian MS, Shupert WL, Bettinotti MP, Marincola FM, Martino L, Hallahan CW, Selig SM, Schwartz D, Sullivan J, Connors M. HLA B$5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci USA 2000, 97:2709-2714. 10.1073/pnas.050567397, 15994, 10694578.
28. den Uyl D, van der Horst-Bruinsma IE, van Agtmael M. Progression of HIV to AIDS: a protective role for HLA-B27?. AIDS Rev 2004, 6:89-96.
29. Barkan SE, Melnick SL, Preston-Martin S, Weber K, Kalish LA, Miotti P, Young M, Greenblatt R, Sacks H, Feldman J. The Women's Interagency HIV Study. WIHS Collaborative Study Group. Epidemiology 1998, 9:117-125. 10.1097/00001648-199803000-00004, 9504278.
30. Muchardt C, Seeler JS, Nirula A, Gong S, Gaynor R. Transcription factor AP-2 activates gene expression of HTLV-I. Embo J 1992, 11:2573-2581. 556732, 1628621.
31. Seeler JS, Muchardt C, Suessle A, Gaynor RB. Transcription factor PRDII-BF1 activates human immunodeficiency virus type 1 gene expression. J Virol 1994, 68:1002-1009. 236538, 8289330.
32. Marban C, Suzanne S, Dequiedt F, de Walque S, Redel L, Van Lint C, Aunis D, Rohr O. Recruitment of chromatin-modifying enzymes by CTIP2 promotes HIV-1 transcriptional silencing. Embo J 2007, 26:412-423. 10.1038/sj.emboj.7601516, 1783449, 17245431.
33. Pumfery A, Deng L, Maddukuri A, de la Fuente C, Li H, Wade JD, Lambert P, Kumar A, Kashanchi F. Chromatin remodeling and modification during HIV-1 Tat-activated transcription. Curr HIV Res 2003, 1:343-362. 10.2174/1570162033485186, 15046258.
34. Shoeman RL, Sachse C, Honer B, Mothes E, Kaufmann M, Traub P. Cleavage of human and mouse cytoskeletal and sarcomeric proteins by human immunodeficiency virus type 1 protease. Actin, desmin, myosin, and tropomyosin. Am J Pathol 1993, 142:221-230. 1886840, 8424456.
35. Parada NA, Cruikshank WW, Danis HL, Ryan TC, Center DM. IL-16-and other CD4 ligand-induced migration is dependent upon protein kinase C. Cell Immunol 1996, 168:100-106. 10.1006/cimm.1996.0054, 8599832.
36. Leghmari K, Bennasser Y, Bahraoui E. HIV-1 Tat protein induces IL-10 production in monocytes by classical and alternative NF-kappaB pathways. Eur J Cell Biol 2008, 87:947-962. 10.1016/j.ejcb.2008.06.005, 18760861.
37. Contreras X, Bennasser Y, Chazal N, Moreau M, Leclerc C, Tkaczuk J, Bahraoui E. Human immunodeficiency virus type 1 Tat protein induces an intracellular calcium increase in human monocytes that requires DHP receptors: involvement in TNF-alpha production. Virology 2005, 332:316-328. 10.1016/j.virol.2004.11.032, 15661163.
38. Bennasser Y, Badou A, Tkaczuk J, Bahraoui E. Signaling pathways triggered by HIV-1 Tat in human monocytes to induce TNF-alpha. Virology 2002, 303:174-180. 10.1006/viro.2002.1676, 12482669.
39. Bennasser Y, Bahraoui E. HIV-1 Tat protein induces interleukin-10 in human peripheral blood monocytes: involvement of protein kinase C-betaII and-delta. Faseb J 2002, 16:546-554. 10.1096/fj.01-0775com, 11919157.
40. Jakobovits A, Rosenthal A, Capon DJ. Trans-activation of HIV-1 LTR-directed gene expression by tat requires protein kinase C. Embo J 1990, 9:1165-1170. 551792, 2182321.
41. Holmes AM. In vitro phosphorylation of human immunodeficiency virus type 1 Tat protein by protein kinase C: evidence for the phosphorylation of amino acid residue serine-46. Arch Biochem Biophys 1996, 335:8-12. 10.1006/abbi.1996.0476, 8914829.
42. Schecter AD, Berman AB, Yi L, Mosoian A, McManus CM, Berman JW, Klotman ME, Taubman MB. HIV envelope gp120 activates human arterial smooth muscle cells. Proc Natl Acad Sci USA 2001, 98:10142-10147. 10.1073/pnas.181328798, 56929, 11504923.
43. Huang MB, Bond VC. Involvement of protein kinase C in HIV-1 gp120-induced apoptosis in primary endothelium. J Acquir Immune Defic Syndr 2000, 25:375-389. 10.1097/00042560-200012150-00001, 11141237.
44. Malumbres M, Barbacid M. Mammalian cyclin-dependent kinases. Trends Biochem Sci 2005, 30:630-641. 10.1016/j.tibs.2005.09.005, 16236519.
45. Ortega S, Malumbres M, Barbacid M. Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta 2002, 1602:73-87.
46. Guo Z, Stiller JW. Comparative genomics of cyclin-dependent kinases suggest co-evolution of the RNAP II C-terminal domain and CTD-directed CDKs. BMC Genomics 2004, 5:69. 10.1186/1471-2164-5-69, 521075, 15380029.
47. Nielsen AL, Oulad-Abdelghani M, Ortiz JA, Remboutsika E, Chambon P, Losson R. Heterochromatin formation in mammalian cells: interaction between histones and HP1 proteins. Mol Cell 2001, 7:729-739. 10.1016/S1097-2765(01)00218-0, 11336697.
48. Smallwood A, Esteve PO, Pradhan S, Carey M. Functional cooperation between HP1 and DNMT1 mediates gene silencing. Genes Dev 2007, 21:1169-1178. 10.1101/gad.1536807, 1865489, 17470536.
49. Loyola A, Tagami H, Bonaldi T, Roche D, Quivy JP, Imhof A, Nakatani Y, Dent SY, Almouzni G. The HP1alpha-CAF1-SetDB1-containing complex provides H3K9me1 for Suv39-mediated K9me3 in pericentric heterochromatin. EMBO Rep 2009, 10:769-775. 10.1038/embor.2009.90, 2727428, 19498464.
50. du Chene I, Basyuk E, Lin YL, Triboulet R, Knezevich A, Chable-Bessia C, Mettling C, Baillat V, Reynes J, Corbeau P, Bertrand E, Marcello A, Emiliani S, Kiernan R, Benkirane M. Suv39H1 and HP1gamma are responsible for chromatin-mediated HIV-1 transcriptional silencing and post-integration latency. Embo J 2007, 26:424-435. 10.1038/sj.emboj.7601517, 1783455, 17245432.
51. Broude EV, Swift ME, Vivo C, Chang BD, Davis BM, Kalurupalle S, Blagosklonny MV, Roninson IB. p21(Waf1/Cip1/Sdi1) mediates retinoblastoma protein degradation. Oncogene 2007, 26:6954-6958. 10.1038/sj.onc.1210516, 17486059.
52. Soni R, Muller L, Furet P, Schoepfer J, Stephan C, Zumstein-Mecker S, Fretz H, Chaudhuri B. Inhibition of cyclin-dependent kinase 4 (Cdk4) by fascaplysin, a marine natural product. Biochem Biophys Res Commun 2000, 275:877-884. 10.1006/bbrc.2000.3349, 10973815.
53. Mahale S, Aubry C, James Wilson A, Jenkins PR, Marechal JD, Sutcliffe MJ, Chaudhuri B. CA224, a non-planar analogue of fascaplysin, inhibits Cdk4 but not Cdk2 and arrests cells at G0/G1 inhibiting pRB phosphorylation. Bioorg Med Chem Lett 2006, 16:4272-4278. 10.1016/j.bmcl.2006.05.065, 16750360.
54. Kubo A, Kaye FJ. Searching for selective cyclin-dependent kinase inhibitors to target the retinoblastoma/p16 cancer gene pathway. J Natl Cancer Inst 2001, 93:415-417. 10.1093/jnci/93.6.415, 11259459.
55. Ammosova T, Berro R, Jerebtsova M, Jackson A, Charles S, Klase Z, Southerland W, Gordeuk VR, Kashanchi F, Nekhai S. Phosphorylation of HIV-1 Tat by CDK2 in HIV-1 transcription. Retrovirology 2006, 3:78. 10.1186/1742-4690-3-78, 1636661, 17083724.
56. Deng L, Ammosova T, Pumfery A, Kashanchi F, Nekhai S. HIV-1 Tat interaction with RNA polymerase II C-terminal domain (CTD) and a dynamic association with CDK2 induce CTD phosphorylation and transcription from HIV-1 promoter. J Biol Chem 2002, 277:33922-33929. 10.1074/jbc.M111349200, 12114499.
57. Nekhai S, Zhou M, Fernandez A, Lane WS, Lamb NJ, Brady J, Kumar A. HIV-1 Tat-associated RNA polymerase C-terminal domain kinase, CDK2, phosphorylates CDK7 and stimulates Tat-mediated transcription. Biochem J 2002, 364:649-657. 10.1042/BJ20011191, 1222613, 12049628.
58. Coley W, Kehn-Hall K, Van Duyne R, Kashanchi F. Novel HIV-1 therapeutics through targeting altered host cell pathways. Expert Opin Biol Ther 2009, 9:1369-1382. 10.1517/14712590903257781, 19732026.
59. Raucher D, Moktan S, Massodi I, Bidwell GL. Therapeutic peptides for cancer therapy. Part II - cell cycle inhibitory peptides and apoptosis-inducing peptides. Expert Opin Drug Deliv 2009, 6:1049-1064. 10.1517/17425240903158909, 19743895.
60. Fahraeus R, Paramio JM, Ball KL, Lain S, Lane DP. Inhibition of pRb phosphorylation and cell-cycle progression by a 20-residue peptide derived from p16CDKN2/INK4A. Curr Biol 1996, 6:84-91. 10.1016/S0960-9822(02)00425-6, 8805225.
61. Fahraeus R, Lane DP. The p16(INK4a) tumour suppressor protein inhibits alphavbeta3 integrin-mediated cell spreading on vitronectin by blocking PKC-dependent localization of alphavbeta3 to focal contacts. Embo J 1999, 18:2106-2118. 10.1093/emboj/18.8.2106, 1171295, 10205165.
62. Kondo E, Seto M, Yoshikawa K, Yoshino T. Highly efficient delivery of p16 antitumor peptide into aggressive leukemia/lymphoma cells using a novel transporter system. Mol Cancer Ther 2004, 3:1623-1630.